It's normal for biotechs to buy intellectual property. It can be risky for a company to underinvest in its own R&D capabilities. 10 stocks we like better than Summit Therapeutics › For most of the ...

Insider buying matters in every industry, but it carries a special weight in biotechnology. In most businesses, management has a reasonably clear view of sales trends, margins, customer demand, and ...

Clinical trials are a key driver of biotech stocks. Every new therapy must pass through a series of testing, Phase 1, Phase 2 ...

FBT selects 30 biotechnology stocks based on sales, sales as a percentage of R&D expenditures, and R&D growth compared to three years ago. The ETF launched 19 years ago and has delivered exceptional ...

SANA develops engineered cell therapies for diabetes, autoimmune diseases, and cancer using ex vivo HIP and in vivo fusogen platforms. SC291 is their CD19‑targeted allogeneic CAR-T candidate which ...

Biotech stocks have a way of making smart people do dumb things. It starts innocently enough. You read about a "breakthrough" that sounds like it came straight out of science fiction. A tiny company ...

The biotech world is a prime target for risk-tolerant investors seeking out companies with the potential for dramatic gains. Firms in this space often either make it big—spiking upon news of a ...

Lixte Biotechnology (ISIN: US53833K1060) develops novel cancer therapies targeting key tumor regulators. North American investors eye its clinical-stage assets amid biotech volatility. Understand the ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...